CC
BIO icon

Claybrook Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Claybrook Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-28
Closed -$7K – 154
2018
Q4 		$7K Buy
+28
New +$7.51K ﹤0.01% 525

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Claybrook Capital's BIO Position: Q1 2019 in Review

Claybrook Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2019, closing a stake of 28 shares — an estimated $7K sold.

Claybrook Capital first reported a position in BIO in Q4 2018 and held it in 1 quarter. The position peaked at $7K in Q4 2018. 346 funds tracked by Wall St. Rank hold BIO as of Q1 2019.

  • Claybrook Capital reported no remaining Bio-Rad Laboratories Class A position as of Q1 2019 after selling out during the quarter.
  • Claybrook Capital sold 28 Bio-Rad Laboratories Class A shares in Q1 2019, an estimated $7K.
  • Claybrook Capital first reported a position in Bio-Rad Laboratories Class A in Q4 2018 and held it in 1 quarter.
  • Claybrook Capital's Bio-Rad Laboratories Class A position peaked at $7K in Q4 2018.
  • 346 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2019.

Based on Claybrook Capital's 13F filing for Q1 2019, filed 15 May 2019.